Tardive dyskinesia can affect many areas of your life, including your social life and self-confidence. Learning how to manage these effects can help improve your overall well-being and daily ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Uncontrollable movements from tardive dyskinesia (TD) can put a strain on your daily life, physically and mentally. Developing a stress management routine, employing social strategies, and seeking ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...